Westside Investment Management Inc. Grows Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB)

Westside Investment Management Inc. grew its stake in shares of INmune Bio, Inc. (NASDAQ:INMB) by 26.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,975 shares of the company’s stock after acquiring an additional 18,660 shares during the period. Westside Investment Management Inc. owned 0.41% of INmune Bio worth $420,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in INMB. Financial Advocates Investment Management lifted its holdings in INmune Bio by 17.4% during the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers bought a new stake in INmune Bio during the 2nd quarter worth approximately $121,000. Jane Street Group LLC purchased a new stake in INmune Bio in the 3rd quarter worth approximately $79,000. Sanctuary Advisors LLC bought a new position in INmune Bio in the 3rd quarter valued at $113,000. Finally, Barclays PLC grew its position in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after purchasing an additional 24,906 shares in the last quarter. 12.72% of the stock is owned by institutional investors.

INmune Bio Price Performance

NASDAQ:INMB opened at $7.44 on Wednesday. The company has a market capitalization of $165.05 million, a price-to-earnings ratio of -3.35 and a beta of 1.78. The business has a 50 day moving average of $5.14 and a 200 day moving average of $6.06. INmune Bio, Inc. has a 1-year low of $4.32 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). During the same period in the previous year, the company posted ($0.48) EPS. As a group, sell-side analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on INMB shares. Raymond James assumed coverage on shares of INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective on the stock. Alliance Global Partners assumed coverage on shares of INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price for the company.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.